Publications

Department of Medicine faculty members published more than 3,000 peer-reviewed articles in 2022.

Filter by

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).

2022

Authors: Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, Florio M, Kassahun H, Melquist S, Varrieur T, Haldar SM, Sohn W, Wang H, Elliott-Davey M, Rock BM, Pei T, Homann O, Hellawell J, Watts GF

BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2.

2022

Authors: Samelson AJ, Tran QD, Robinot R, Carrau L, Rezelj VV, Kain AM, Chen M, Ramadoss GN, Guo X, Lim SA, Lui I, Nuñez JK, Rockwood SJ, Wang J, Liu N, Carlson-Stevermer J, Oki J, Maures T, Holden K, Weissman JS, Wells JA, Conklin BR, TenOever BR, Chakrabarti LA, Vignuzzi M, Tian R, Kampmann M

AI as a new paradigm for risk-based screening for breast cancer.

2022

Authors: Houssami N, Kerlikowske K

Optimizing Health and Athletic Performance for Women.

2022

Authors: de Borja C, Chang CJ, Watkins R, Senter C

Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma.

2022

Authors: Al-Shaikhly T, Murphy RC, Parker A, Lai Y, Altman MC, Larmore M, Altemeier WA, Frevert CW, Debley JS, Piliponsky AM, Ziegler SF, Peters MC, Hallstrand TS

Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population.

2022

Authors: Kerlikowske K, Chen S, Golmakani MK, Sprague BL, Tice JA, Tosteson ANA, Rauscher GH, Henderson LM, Buist DSM, Lee JM, Gard CC, Miglioretti DL

Volume 37 of Issue 15 | Journal of general internal medicine

Reduced Emergency Department Visits and Hospitalisation with Use of an Unsanctioned Safe Consumption Site for Injection Drug Use in the United States.

2022

Authors: Lambdin BH, Davidson PJ, Browne EN, Suen LW, Wenger LD, Kral AH

View Abstract

BACKGROUND

Safe consumption sites (SCS) are an evidence-based intervention to prevent drug use-related harm. In late 2014, an organisation in an undisclosed location in the USA opened an unsanctioned SCS.

OBJECTIVE

To evaluate whether use of the unsanctioned SCS affected medical outcomes.

DESIGN

A prospective cohort study.

SETTING

Neighbourhoods surrounding the SCS.

PARTICIPANTS

People who injected drugs were recruited and interviewed at baseline and 6 and 12 months from 2018 to 2020.

INTERVENTION

People using the SCS could bring pre-obtained drugs to consume via injection, which were monitored by trained staff with naloxone.

MAIN MEASURES

Any overdose, number of non-fatal overdoses, skin and soft tissue infections, emergency department utilisation, number of emergency department visits, hospitalisation and number of nights spent in hospital.

KEY RESULTS

A total of 494 participants enrolled in the study; 59 (12%) used the SCS at least once. We used propensity score weighting to analyse the association between SCS utilisation and measures. People using the SCS were 27% (95% CI: 12-46%) less likely to visit the emergency department, had 54% (95% CI: 33-71%) fewer emergency department visits, were 32% (95% CI: 4-57%) less likely to be hospitalised, and spent 50% (95% CI: 1-85%) fewer nights in hospital. Though not significant, people using the SCS had a lower likelihood of overdosing and slightly higher likelihood of skin and soft tissue infections.